Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FGF1 | P05230 | 5/20 | 0.35 |
| ▸ | FGF2 | P09038 | 3/20 | 0.35 |
| ▸ | VEGFA | P15692 | 3/20 | 0.35 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398993 | 1.00 | SELP (0.36) | SELPLMNAFGF1FGF2VEGFA | |
| SCHEMBL13224918 | 1.00 | SELP (0.36) | SELPLMNAFGF1FGF2VEGFA | |
| SCHEMBL2530520 | 1.00 | SELP (0.36) | SELPLMNAFGF1FGF2VEGFA | |
| SCHEMBL13248405 | 0.94 | SELP (0.37) | SELPLMNAFGF1FGF2VEGFA | |
| SCHEMBL2175355 | 0.84 | FGF1 (0.44) | SELPFGF1FGF2VEGFAHPSE | |
| SCHEMBL6929305 | 0.84 | FGF1 (0.44) | SELPFGF1FGF2VEGFAHPSE | |
| SCHEMBL6923504 | 0.84 | FGF1 (0.44) | SELPFGF1FGF2VEGFAHPSE | |
| SCHEMBL13057268 | 0.84 | FGF1 (0.44) | SELPFGF1FGF2VEGFAHPSE | |
| SCHEMBL13224912 | 0.81 | TGM2 (0.38) | LMNAGAATGM2MEN1KMT2A | |
| SCHEMBL13224917 | 0.81 | FGF1 (0.40) | SELPLMNAFGF1FGF2VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2388264-A1 | COMPOUND RETAINED IN TUMOR | Toyo Suisan Kaisha, Ltd. (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20110254443-A1 | PHASE AND FREQUENCY LOCKED MAGNETRON | MUONS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20100202971-A1 | COMPOUND HAVING TUMOR-RESIDENT PROPERTY | OHTA KEISUKE | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100202971-A1 | COMPOUND HAVING TUMOR-RESIDENT PROPERTY | HRH3, HRH4, HNRNPH3 | SELP 3654/4885LMNA 3710/4885FGF1 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.